- Burosumab users see stable phosphorus levels after eating
- Helps kids and adults with rare bone disorder XLH
- Could ease clinic visits—still needs confirmation
This could make life easier for families managing a lifelong condition.
Imagine rushing your child to a morning blood draw, stomach empty, hungry and fussy—only to find out the results might not even require fasting anymore. For families living with X-linked hypophosphatemia (XLH), that stress could soon be a thing of the past.
XLH is a rare genetic disorder that weakens bones and slows growth in children. It affects about 1 in 20,000 people. The body loses too much phosphate through urine, which is critical for strong bones and teeth. Without enough phosphate, kids can develop rickets, bowed legs, and dental problems. Adults face bone pain, fractures, and stiffness.
For years, treatment meant taking phosphate supplements and active vitamin D multiple times a day. It was messy. Dosing had to be exact. And blood tests always required fasting—usually first thing in the morning, before breakfast.
But here’s the twist: a new treatment called burosumab changed the game. It’s a monthly injection that targets the root cause—too much of a hormone called FGF23. This hormone acts like a “stop sign” for phosphate. Burosumab blocks it, letting the kidneys hold onto more phosphate naturally.
Why this matters now Fewer pills. Better bone healing. Improved growth in kids. Burosumab has been a major step forward. But doctors still insisted on fasting blood tests to check phosphate levels. The rule was clear: no food before the lab visit. Otherwise, results might be off.
That made life harder. Parents juggled early appointments. Adults took time off work. Missed meals led to low energy. And if a child ate a cracker on the way? The test might be delayed.
The surprising shift Now, new data suggest those strict rules may no longer be necessary—for patients already on stable burosumab treatment.
Here’s how it works Think of phosphate like fuel for your bones. In XLH, the body leaks fuel because of a broken “sensor” (FGF23). Burosumab fixes the sensor, so the body stops leaking. Once that system is balanced, eating doesn’t cause big spikes or drops in phosphate—unlike with older treatments.
It’s like fixing a leaky gas tank. Once sealed, driving (or eating) doesn’t change your fuel level dramatically.
Study snapshot Researchers looked at 39 people—13 children and 26 adults—already on burosumab for at least a year. They measured phosphate and calcium in the blood before breakfast, then again 1 and 2 hours after eating. Adults also had levels checked after lunch.
What they found Phosphate levels barely changed after meals. In both kids and adults, the average levels stayed steady. No clinically meaningful rise or drop was seen.
Calcium levels stayed in the normal range for all children and nearly all adults. That’s important—because high calcium can lead to kidney issues.
One adult had a temporary calcium increase after eating, but it didn’t last. Otherwise, no safety concerns popped up.
This doesn’t mean this treatment is available yet.
But there’s a catch. While the average results were stable, not everyone responded the same. Some people had slight swings in phosphate after eating. That means doctors still need to be cautious.
What scientists didn’t expect They thought meals might cause bigger changes. But the body’s response under burosumab appears more stable than expected. That’s likely because the drug creates a steady, ongoing correction—unlike older treatments that caused peaks and valleys with each dose.
Expert perspective This study adds real-world value. It suggests that for patients on long-term, stable burosumab, fasting may no longer be essential for accurate monitoring. That aligns with how the drug works: it provides a consistent effect, day after day.
This could reduce the burden on families and clinics. It also opens the door to more flexible testing—like afternoon appointments or using non-fasting labs during urgent visits.
What this means for you If you or your child is on burosumab, this news may simplify life. You might not need to fast before every blood test. But don’t change your routine yet. Talk to your doctor. They’ll know if your treatment is stable enough to consider non-fasting tests.
This isn’t a green light for everyone. Kids just starting burosumab, or those with kidney concerns, may still need fasting checks. But for many, this could be a small but meaningful relief.
Limitations The study was small—only 39 people. It only looked at one meal type and short-term changes. It didn’t test high-phosphate meals, which might affect results differently. And it didn’t include very young children or those with other health conditions.
The road ahead Doctors may soon update guidelines to allow non-fasting blood tests for stable XLH patients on burosumab. Larger studies could confirm these findings across more diverse diets and age groups. For now, this is a promising step toward less stress and more flexibility in managing XLH.